BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 26206648)

  • 1. Results of (68)Gallium-DOTATATE PET/CT Scanning in Patients with Multiple Endocrine Neoplasia Type 1.
    Sadowski SM; Millo C; Cottle-Delisle C; Merkel R; Yang LA; Herscovitch P; Pacak K; Simonds WF; Marx SJ; Kebebew E
    J Am Coll Surg; 2015 Aug; 221(2):509-17. PubMed ID: 26206648
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospective Study of 68Ga-DOTATATE Positron Emission Tomography/Computed Tomography for Detecting Gastro-Entero-Pancreatic Neuroendocrine Tumors and Unknown Primary Sites.
    Sadowski SM; Neychev V; Millo C; Shih J; Nilubol N; Herscovitch P; Pacak K; Marx SJ; Kebebew E
    J Clin Oncol; 2016 Feb; 34(6):588-96. PubMed ID: 26712231
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of (68)Ga-DOTATATE PET/CT in patients with multiple endocrine neoplasia type 1 (MEN1).
    Lastoria S; Marciello F; Faggiano A; Aloj L; Caracò C; Aurilio M; D'Ambrosio L; Di Gennaro F; Ramundo V; Camera L; De Luca L; Fonti R; Napolitano V; Colao A
    Endocrine; 2016 Jun; 52(3):488-94. PubMed ID: 26242621
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The lesion detection rate of Ga-68 DOTATATE PET/MR in multiple endocrine neoplasia type 1.
    Gao J; Liu C; Zhou J; Pan Y; Zhang Y
    J Med Imaging Radiat Oncol; 2024 Apr; 68(3):250-256. PubMed ID: 38563291
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT within patients with gastroenteropancreatic neuroendocrine tumors.
    Wild D; Bomanji JB; Benkert P; Maecke H; Ell PJ; Reubi JC; Caplin ME
    J Nucl Med; 2013 Mar; 54(3):364-72. PubMed ID: 23297077
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of diagnostic accuracy of (111)In-pentetreotide SPECT and (68)Ga-DOTATOC PET/CT: A lesion-by-lesion analysis in patients with metastatic neuroendocrine tumours.
    Van Binnebeek S; Vanbilloen B; Baete K; Terwinghe C; Koole M; Mottaghy FM; Clement PM; Mortelmans L; Bogaerts K; Haustermans K; Nackaerts K; Van Cutsem E; Verslype C; Verbruggen A; Deroose CM
    Eur Radiol; 2016 Mar; 26(3):900-9. PubMed ID: 26162577
    [TBL] [Abstract][Full Text] [Related]  

  • 7.
    El-Maouche D; Sadowski SM; Papadakis GZ; Guthrie L; Cottle-Delisle C; Merkel R; Millo C; Chen CC; Kebebew E; Collins MT
    J Clin Endocrinol Metab; 2016 Oct; 101(10):3575-3581. PubMed ID: 27533306
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    Hope TA; Calais J; Zhang L; Dieckmann W; Millo C
    J Nucl Med; 2019 Sep; 60(9):1266-1269. PubMed ID: 30850506
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gallium-68 Dotatate PET/CT is superior to other imaging modalities in the detection of medullary carcinoma of the thyroid in the presence of high serum calcitonin.
    Tran K; Khan S; Taghizadehasl M; Palazzo F; Frilling A; Todd JF; Al-Nahhas A
    Hell J Nucl Med; 2015; 18(1):19-24. PubMed ID: 25679074
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 64Cu-DOTATATE PET for Neuroendocrine Tumors: A Prospective Head-to-Head Comparison with 111In-DTPA-Octreotide in 112 Patients.
    Pfeifer A; Knigge U; Binderup T; Mortensen J; Oturai P; Loft A; Berthelsen AK; Langer SW; Rasmussen P; Elema D; von Benzon E; Højgaard L; Kjaer A
    J Nucl Med; 2015 Jun; 56(6):847-54. PubMed ID: 25952736
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of (68)Ga-DOTA-TOC PET/CT for the detection of duodenopancreatic neuroendocrine tumors in patients with MEN1.
    Morgat C; Vélayoudom-Céphise FL; Schwartz P; Guyot M; Gaye D; Vimont D; Schulz J; Mazère J; Nunes ML; Smith D; Hindié E; Fernandez P; Tabarin A
    Eur J Nucl Med Mol Imaging; 2016 Jul; 43(7):1258-66. PubMed ID: 26819103
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The utility of
    Shell J; Tirosh A; Millo C; Sadowski SM; Assadipour Y; Green P; Patel D; Nilubol N; Kebebew E
    Eur J Radiol; 2019 Mar; 112():130-135. PubMed ID: 30777201
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 68Ga-DOTATATE PET/CT, 99mTc-HYNIC-octreotide SPECT/CT, and whole-body MR imaging in detection of neuroendocrine tumors: a prospective trial.
    Etchebehere EC; de Oliveira Santos A; Gumz B; Vicente A; Hoff PG; Corradi G; Ichiki WA; de Almeida Filho JG; Cantoni S; Camargo EE; Costa FP
    J Nucl Med; 2014 Oct; 55(10):1598-604. PubMed ID: 25168627
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differences in tumor-to-normal organ SUV ratios measured with 68 Ga-DOTATATE PET compared with 177 Lu-DOTATATE SPECT in patients with neuroendocrine tumors.
    Wong KK; Frey KA; Niedbala J; Kaza RK; Worden FP; Fitzpatrick KJ; Dewaraja YK
    Nucl Med Commun; 2022 Aug; 43(8):892-900. PubMed ID: 35703269
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gallium-68-dotatate PET/CT is better than CT in the management of somatostatin expressing tumors: First experience in Africa.
    Lawal IO; Ololade KO; Lengana T; Reyneke F; Ankrah AO; Ebenhan T; Vorster M; Sathekge MM
    Hell J Nucl Med; 2017; 20(2):128-133. PubMed ID: 28697189
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Limited Value of Ga-68-DOTATOC-PET-CT in Routine Screening of Patients with Multiple Endocrine Neoplasia Type 1.
    Albers MB; Librizzi D; Lopez CL; Manoharan J; Apitzsch JC; Slater EP; Bollmann C; Kann PH; Bartsch DK
    World J Surg; 2017 Jun; 41(6):1521-1527. PubMed ID: 28138732
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and Efficacy of 68Ga-DOTATATE PET/CT for Diagnosis, Staging, and Treatment Management of Neuroendocrine Tumors.
    Deppen SA; Liu E; Blume JD; Clanton J; Shi C; Jones-Jackson LB; Lakhani V; Baum RP; Berlin J; Smith GT; Graham M; Sandler MP; Delbeke D; Walker RC
    J Nucl Med; 2016 May; 57(5):708-14. PubMed ID: 26769865
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional imaging of neuroendocrine tumors with combined PET/CT using 68Ga-DOTATATE (DOTA-DPhe1,Tyr3-octreotate) and 18F-FDG.
    Kayani I; Bomanji JB; Groves A; Conway G; Gacinovic S; Win T; Dickson J; Caplin M; Ell PJ
    Cancer; 2008 Jun; 112(11):2447-55. PubMed ID: 18383518
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Value of Somatostatin Receptor PET/CT in Patients With MEN1 at Various Stages of Their Disease.
    Mennetrey C; Le Bras M; Bando-Delaunay A; Al-Mansour L; Haissaguerre M; Batisse-Lignier M; Ouvrard E; Ansquer C; Walter T; de Mestier L; Kelly A; Tlili G; Giraud S; North MO; Odou MF; Goichot B; Cuny T; Loundou A; Romanet P; Imperiale A; Taïeb D
    J Clin Endocrinol Metab; 2022 Apr; 107(5):e2056-e2064. PubMed ID: 34940846
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The value of
    Liu KY; Goldrich DY; Ninan SJ; Filimonov A; Lam H; Govindaraj S; Iloreta AM
    Head Neck; 2021 Jun; 43(6):E30-E40. PubMed ID: 33786927
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.